Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström's Macroglobulinemia

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Blood

Topics

Cancer Oncology

Internal Medicine

Medicine

Cancer Oncology

Internal Medicine

Genetics

Multiple Myeloma

Show all topics

DOI

10.1182/blood-2024-200604